Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 133Squamous Cell Carcinoma of Head and Neck 76Lung Neoplasms 49Head and Neck Neoplasms 45Urinary Bladder Neoplasms 43Parkinson Disease 4, Autosomal Dominant Lewy Body 33Oropharyngeal Neoplasms 32Nasopharyngeal Carcinoma 32Biliary Tract Neoplasms 31Uterine Cervical Neoplasms 30Cholangiocarcinoma 28Esophageal Squamous Cell Carcinoma 26Carcinoma 24Neoplasms 23Ovarian Neoplasms 22Neoplasm Metastasis 22Small Cell Lung Carcinoma 21Carcinoma, Squamous Cell 20Stomach Neoplasms 18Colorectal Neoplasms 18Carcinoma, Transitional Cell 17Pancreatic Neoplasms 16Esophageal Neoplasms 16Mesothelioma, Malignant 15Gallbladder Neoplasms 15Mouth Neoplasms 14Laryngeal Neoplasms 13Hypopharyngeal Neoplasms 12Endometrial Neoplasms 11Triple Negative Breast Neoplasms 10

Interventions

pembrolizumab 1fludarabine 1Radiotherapy, Intensity-Modulated 1Losartan 1LY3300054 1Gemcitabine 1Cyclophosphamide 1Cisplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Camurati-Engelmann Syndrome × Cisplatin × 1 year × Clear all
NCT02937272 2026-04-03

A Study of LY3200882 in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
223 enrolled

Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡